KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Current Deferred Revenue: 2010-2022

Historic Current Deferred Revenue for Emergent BioSolutions (EBS) over the last 12 years, with Mar 2022 value amounting to $15.9 million.

  • Emergent BioSolutions' Current Deferred Revenue fell 85.90% to $15.9 million in Q1 2022 from the same period last year, while for Mar 2022 it was $15.9 million, marking a year-over-year decrease of 85.90%. This contributed to the annual value of $16.4 million for FY2021, which is 83.62% down from last year.
  • According to the latest figures from Q1 2022, Emergent BioSolutions' Current Deferred Revenue is $15.9 million, which was down 3.05% from $16.4 million recorded in Q4 2021.
  • Over the past 5 years, Emergent BioSolutions' Current Deferred Revenue peaked at $118.0 million during Q2 2020, and registered a low of $9.8 million during Q2 2018.
  • Moreover, its 3-year median value for Current Deferred Revenue was $89.4 million (2020), whereas its average is $79.8 million.
  • As far as peak fluctuations go, Emergent BioSolutions' Current Deferred Revenue spiked by 817.95% in 2019, and later slumped by 85.90% in 2022.
  • Emergent BioSolutions' Current Deferred Revenue (Quarterly) stood at $73.1 million in 2018, then rose by 21.61% to $88.9 million in 2019, then climbed by 12.60% to $100.1 million in 2020, then plummeted by 83.62% to $16.4 million in 2021, then slumped by 85.90% to $15.9 million in 2022.
  • Its last three reported values are $15.9 million in Q1 2022, $16.4 million for Q4 2021, and $82.1 million during Q3 2021.